<code id='F26A99EE73'></code><style id='F26A99EE73'></style>
    • <acronym id='F26A99EE73'></acronym>
      <center id='F26A99EE73'><center id='F26A99EE73'><tfoot id='F26A99EE73'></tfoot></center><abbr id='F26A99EE73'><dir id='F26A99EE73'><tfoot id='F26A99EE73'></tfoot><noframes id='F26A99EE73'>

    • <optgroup id='F26A99EE73'><strike id='F26A99EE73'><sup id='F26A99EE73'></sup></strike><code id='F26A99EE73'></code></optgroup>
        1. <b id='F26A99EE73'><label id='F26A99EE73'><select id='F26A99EE73'><dt id='F26A99EE73'><span id='F26A99EE73'></span></dt></select></label></b><u id='F26A99EE73'></u>
          <i id='F26A99EE73'><strike id='F26A99EE73'><tt id='F26A99EE73'><pre id='F26A99EE73'></pre></tt></strike></i>

          Wikipedia

          Wikipedia

          author:comprehensive    Page View:71779
          Mayo Clinic, in Rochester, Minnesota on
          Photo by KEREM YUCEL/AFP via Getty Images

          SAN FRANCISCO — Mayo Clinic has signed Silicon Valley tech startup Cerebras as its first generative AI partner, the health system announced Monday.

          The health system — known for its cutting-edge research and willingness to partner with tech companies — will give Cerebras millions of dollars to help build technology tools based on Mayo’s trove of de-identified patient data, leaders announced at the J.P. Morgan Healthcare Conference. Mayo and Cerebras did not disclose the dollar amount, but Cerebras said it was a multimillion, multi-year contract.

          advertisement

          With roughly 380 employees, Cerebras builds and sells supercomputers specifically designed for AI applications across several industries — pitting the upstart in direct competition with the market leader Nvidia Corp. Life sciences giants including GSK have used its technology for drug discovery, and it has partnered with a health network in United Arab Emirates, but this is Cerebras’ first AI contract with a U.S. health system. The deal gives Mayo access to Cerebras’ supercomputers as well as a Cerebras team to help develop health-tuned models; Mayo will then own whatever they build.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          Moonlake's readout produced a cash windfall. Risks remain
          Moonlake's readout produced a cash windfall. Risks remain

          MollyFerguson/STATFortwodaysstartingonSunday,MoonlakeImmunotherapeuticshappilycrunchednumbersandshar

          read more
          FDA approves Moderna’s RSV vaccine, its second licensed product
          FDA approves Moderna’s RSV vaccine, its second licensed product

          TheFDAhasapprovedModerna’sRSVvaccineforolderadults.ModernaTheFoodandDrugAdministrationonFridayapprov

          read more
          Trump demands the U.S. pay no more for drugs than other countries … again
          Trump demands the U.S. pay no more for drugs than other countries … again

          EthanMiller/GettyImagesWASHINGTON—FormerPresidentTrumpisbacktocampaigningfortyingMedicaredrugpricest

          read more

          An outdated Medicare rule harms dementia patients with anxiety

          CarstenKoall/GettyImagesMemorylossisthemostobvioussymptomofAlzheimer’sdisease.Butforthemorethan6.5mi